Logo

American Heart Association

  5
  0


Final ID: LBP10

Impact of Door-In-Door-Out Times on Functional Outcomes in Patients with Stroke Transferred for Endovascular Therapy

Abstract Body: Intro: Interhospital transfer (IHT) is often required for endovascular therapy (EVT) for acute ischemic stroke (AIS) patients. The door-in-door-out (DIDO) times for patients who require EVT are often longer than the recommended 90 min (excellent) or 120 min (adequate) targets; yet, it is unknown how delays impact functional outcomes.

Methods: This was a cohort study of prospectively collected data of patients in the American Heart Association Get With The Guidelines®-Stroke registry with AIS who underwent EVT from Jan 2019 to Dec 2023 and were transferred from the ED at the presenting hospital to a thrombectomy-performing hospital. Patients were included if a potential target lesion for EVT was visualized during CT, MR, or catheter angiography. The primary outcome was level of disability at discharge (ordinal modified Rankin Scale, mRS); secondary outcomes included discharge ambulatory status (without assistance/with assistance/non-ambulatory/death) and mRS dichotomies at discharge of ambulatory and of self-care capable (mRS 0-3) and functional independence (mRS 0-2). Mixed effects models with random intercepts to account for clustering by hospital were used with sequential adjustment for demographics and risk factors, hospital characteristics, patient characteristics on admission to the thrombectomy hospital (including NIHSS score), and treatment characteristics (including use of intravenous thrombolysis, TICI reperfusion status, LVO location, and post-procedure complications).

Results: Among 29,511 patients (50.3% male, mean age 68.8 [SD:14.6] years, 74.0% White), 37.5% had DIDO time ≤90 mins, 39.8% 91-180 mins, 10.2% 181-270 mins, and 12.5% were >270 mins. In the model fully adjusting for arrival characteristics (Model 4), patients with longer DIDO times had higher odds of a one-point increase in discharge mRS (91-180 vs ≤90 mins: aOR 1.16 (95% CI 1.08, 1.24); 181-270 vs ≤90 mins: aOR 1.49 (95% CI 1.35, 1.66); >270 vs ≤90 mins: aOR 1.61 (95% CI 1.46, 1.78). This relationship remained when controlling for treatment characteristics (Model 5). Similar statistically significant increases in unfavorable outcomes with longer DIDO were observed for all secondary outcomes.

Discussion: Longer DIDO times were associated with greater disability outcomes and reduced independent ambulation at discharge in AIS patients transferred for EVT. Further efforts must be made to optimize the rapid evaluation and interhospital transfer of stroke patients eligible for EVT.
  • Royan, Regina  ( University of Michigan , Ann Arbor , Michigan , United States )
  • Stamm, Brian  ( University of Michigan , Ann Arbor , Michigan , United States )
  • Giurcanu, Mihai  ( University of Chicago , Chicago , Illinois , United States )
  • Jauch, Edward  ( UNC Health Sciences at MAHEC , Mills River , North Carolina , United States )
  • Messe, Steven  ( University of Pennsylvania , Philadelphia , Pennsylvania , United States )
  • Saver, Jeffrey  ( GEFFEN SCHOOL OF MEDICINE AT UCLA , Los Angeles , California , United States )
  • Prabhakaran, Shyam  ( University of Chicago , Chicago , Illinois , United States )
  • Author Disclosures:
    Regina Royan: DO NOT have relevant financial relationships | Brian Stamm: DO NOT have relevant financial relationships | Mihai Giurcanu: DO NOT have relevant financial relationships | Edward Jauch: DO have relevant financial relationships ; Consultant:Rapid.AI:Active (exists now) | Steven Messe: DO NOT have relevant financial relationships | Jeffrey Saver: DO have relevant financial relationships ; Consultant:Abbott:Active (exists now) ; Individual Stocks/Stock Options:Viz.ai:Active (exists now) ; Individual Stocks/Stock Options:Let's Get Proof:Active (exists now) ; Individual Stocks/Stock Options:Neuronics:Active (exists now) ; Consultant:Genentech:Expected (by end of conference) ; Consultant:Roche:Active (exists now) ; Consultant:Novo Nordisc:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:BrainQ:Active (exists now) ; Consultant:Medtronic:Active (exists now) | Shyam Prabhakaran: DO NOT have relevant financial relationships
Meeting Info:
Session Info:

Late-Breaking Science Posters

Wednesday, 02/05/2025 , 07:00PM - 07:30PM

Poster Abstract Session

More abstracts on this topic:
A Trial of Patients Receiving Remote Ischemic Conditioning in Early Stroke (PRICES) in a Tertiary Hospital in the Philippines: An Open Label Study

Ang Kevin Royce, Juangco Dan, Hernandez Maria Kim

A Pilot Trial on Middle Meningeal Artery Embolization to Treat Migraine Headache

Ren Zeguang, Xiang Xin, Yang Hua, Chu Liangzhao, Wu Shan, Song Shibin, Zheng Yan, Xu Kaya, Cui Junshuan, Demiraj Francis, Chen Guangtang, Wang Qingqing, Mokin Maxim, Huang Yuanxin, Peng Zhongyong

More abstracts from these authors:
M*A*S*H: Moving Care to The Field
(Moderator)

Royan Regina

Derivation and Validation of the Get with the Guidelines®-Stroke Endovascular Thrombectomy Risk Scores

Lusk Jay, Bhatt Deepak, Saver Jeffrey, Mac Grory Brian, Brown Scott, Hassan Ameer, Albers Gregory, Fonarow Gregg, Schwamm Lee, Messe Steven, Smith Eric, Hasan David

You have to be authorized to contact abstract author. Please, Login
Not Available

Readers' Comments

We encourage you to enter the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and simulate conversation and knowledge sharing.

 

You have to be authorized to post a comment. Please, Login or Signup.


   Rate this abstract  (Maximum characters: 500)